Dr. Reddy's Laboratories (RDY) Competitors

-0.56 (-0.78%)
(As of 04/24/2024 ET)


Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Karuna Therapeutics (KRTX), BeiGene (BGNE), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Viatris (VTRS), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical preparations" industry.

Dr. Reddy's Laboratories vs.

Dr. Reddy's Laboratories (NYSE:RDY) and Karuna Therapeutics (NASDAQ:KRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Dr. Reddy's Laboratories has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Dr. Reddy's Laboratories received 195 more outperform votes than Karuna Therapeutics when rated by MarketBeat users. However, 66.29% of users gave Karuna Therapeutics an outperform vote while only 58.95% of users gave Dr. Reddy's Laboratories an outperform vote.

Dr. Reddy's LaboratoriesOutperform Votes
Underperform Votes
Karuna TherapeuticsOutperform Votes
Underperform Votes

14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 13.2% of Karuna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 19.26% compared to Karuna Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 20.97% beat Karuna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories19.26% 20.97% 15.19%
Karuna Therapeutics N/A -31.63%-30.38%

Dr. Reddy's Laboratories currently has a consensus price target of $80.00, suggesting a potential upside of 12.79%. Karuna Therapeutics has a consensus price target of $293.92, suggesting a potential downside of 10.89%. Given Dr. Reddy's Laboratories' higher possible upside, research analysts clearly believe Dr. Reddy's Laboratories is more favorable than Karuna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Karuna Therapeutics
0 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Karuna Therapeutics. MarketBeat recorded 2 mentions for Dr. Reddy's Laboratories and 1 mentions for Karuna Therapeutics. Karuna Therapeutics' average media sentiment score of 0.00 beat Dr. Reddy's Laboratories' score of -0.02 indicating that Karuna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Karuna Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Dr. Reddy's Laboratories has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.99B3.96$548M$3.7918.72
Karuna Therapeutics$654K19,239.07-$433.68M-$11.72-28.14


Dr. Reddy's Laboratories beats Karuna Therapeutics on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

MetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$11.93B$6.54B$4.90B$17.45B
Dividend Yield0.57%3.06%2.96%3.54%
P/E Ratio18.728.09191.0121.66
Price / Sales3.96298.402,453.1510.24
Price / Cash16.9729.5646.1817.74
Price / Book4.205.524.624.91
Net Income$548M$139.05M$103.04M$964.49M
7 Day Performance0.01%-0.48%0.30%2.27%
1 Month Performance-3.38%-8.84%-5.24%-2.07%
1 Year Performance19.67%-2.51%9.06%91.79%

Dr. Reddy's Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Karuna Therapeutics
0.0579 of 5 stars
+63.2%$12.58B$654,000.00-28.14339Upcoming Earnings
2.9219 of 5 stars
-44.0%$12.82B$2.46B-15.7710,600Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Sarepta Therapeutics
4.8756 of 5 stars
-1.9%$11.01B$1.24B-19.171,314Analyst Revision
News Coverage
United Therapeutics
4.4104 of 5 stars
+3.8%$10.91B$2.33B11.681,168Upcoming Earnings
Insider Selling
News Coverage
1.2428 of 5 stars
+23.8%$13.34B$15.43B278.0038,000Positive News
3.1927 of 5 stars
+24.4%$10.08B$4.28B-8.2017,800Positive News
Teva Pharmaceutical Industries
0.7952 of 5 stars
Legend Biotech
2.4523 of 5 stars
-33.6%$9.12B$285.14M-33.861,800Analyst Report
High Trading Volume
Ascendis Pharma A/S
1.3605 of 5 stars
+79.5%$8.24B$288.08M-15.30879Analyst Report
News Coverage
Intra-Cellular Therapies
4.307 of 5 stars
+17.5%$7.73B$464.37M-54.68610Upcoming Earnings
Analyst Report
High Trading Volume

Related Companies and Tools

This page (NYSE:RDY) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners